Inoxgen (Nitric Oxide)

Nitric oxide released from Inoxgen activates soluble guanylate cyclase in the smooth‑muscle cells of the pulmonary vasculature. This activation raises cyclic GMP levels, causing relaxation of the pulmonary arteries and resulting in selective vasodilation that improves blood flow and gas exchange without markedly affecting systemic circulation.

The dose of Inoxgen is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosage is individualized and administered via a specialized inhalation delivery system under medical supervision; exact dosing regimens are not publicly disclosed.

Safety data for Inoxgen in pregnancy and lactation are limited. Because the effects on the fetus or nursing infant are not well established, it should be used only if the potential benefit justifies any potential risk, and only under close medical supervision.

To order Inoxgen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Inoxgen delivers nitric oxide directly to the lungs, offering rapid and reversible pulmonary vasodilation. Compared with inhaled prostacyclin analogues, nitric oxide has a shorter half‑life and allows precise titration, but both classes aim to lower pulmonary pressure. Choice of therapy depends on patient-specific factors, drug availability, and clinician preference.

Inoxgen should be stored at ambient temperature, ideally below 25 °C, in its original sealed container. Protect the gas from moisture, direct sunlight, and physical damage. Follow the manufacturer’s handling instructions to maintain gas purity and ensure safe administration.

Inoxgen is administered by inhalation using a calibrated delivery system that mixes the gas with the patient’s breathing circuit. The administration is performed under continuous monitoring of respiratory and hemodynamic parameters to adjust the dose as needed and to detect any adverse effects promptly.

The most serious risks include systemic hypotension, which can compromise blood pressure, methemoglobinemia, a rare condition that impairs oxygen transport, and pulmonary edema, which may worsen respiratory status. Patients should be closely monitored for these events, especially during dose escalation.

Inoxgen is contraindicated in patients with severe anemia, known hypersensitivity to nitric oxide, uncontrolled systemic hypotension, or those receiving other potent pulmonary vasodilators without careful supervision. Clinicians should also exercise caution in neonates with certain cardiac defects and in pregnant or breastfeeding women when safer alternatives exist.